ImmunityBio (IBRX) Liabilities and Shareholders Equity (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Liabilities and Shareholders Equity data on file, last reported at $646.6 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $646.6 million, up 112.88% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.1 billion (up 38.38% YoY), and the FY2025 annual result was $501.9 million, up 31.07% from the prior year.
• Liabilities and Shareholders Equity rose to $646.6 million in Q1 2026 per IBRX's latest filing, from $501.9 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $646.6 million in Q1 2026 and troughed at $291.2 million in Q2 2023.
• A 5-year average of $409.4 million and a median of $389.6 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2025 and 2026: Liabilities and Shareholders Equity slipped 24.19% in 2025, then surged 112.88% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $362.4 million in 2022, then surged by 39.21% to $504.5 million in 2023, then decreased by 24.09% to $382.9 million in 2024, then surged by 31.07% to $501.9 million in 2025, then climbed by 28.84% to $646.6 million in 2026.
• Business Quant data shows IBRX's Liabilities and Shareholders Equity at $646.6 million in Q1 2026, $501.9 million in Q4 2025, and $519.0 million in Q3 2025.